Please login to the form below

Not currently logged in
Email:
Password:

US regulatory science awards announced

The US National Institutes of Health and the US Food and Drug Administration will partner on a scheme to award research projects in regulatory science

The US National Institutes of Health (NIH) and the US Food and Drug Administration (FDA) will partner on a scheme to award four research projects in regulatory science.

The NIH will award $9.4m over three years to projects which "better inform scientists and regulatory reviewers alike about medical product safety, and improve the evaluation and availability of new medical products to the community." The FDA will contribute $950,000 to the scheme.

Projects set to be recipients of the award include research by Dr Dennis E Hourcade on nanoparticles and work by researchers at the University of Michigan into innovative clinical trial design.

The other two projects are the development of an innovative heart/lung model by Dr Donald E Ingber, Harvard University Medical School, to test drug safety, and MB Research Laboratories' novel strategy to predict eye irritation.

"These four projects were chosen among many applications because they were the most meritorious proposals for addressing high priority areas in cutting-edge biomedical research and regulatory science," said NIH director, Dr Francis S Collins.

He continued: "This partnership marks the beginning of our work with the FDA to use new scientific and technological tools to aid/enhance the review of new drugs and devices. It is one facet of our shared commitment to speed the delivery of new medical products to patients."

The awards continue a commitment from both agencies made in February 2010 to work together on important public health issues under the NIH-FDA Joint Leadership Council.

29th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics